1 / 45

Director’s Report to the National Advisory Council on Drug Abuse

Director’s Report to the National Advisory Council on Drug Abuse. May 17, 2005. Director’s Report to the National Advisory Council on Drug Abuse. Budget Update. Policy Issues. Recent NIDA Activities & Events. Budget Update. 2005 Appropriation. 2006 P.B. 2004 Actual. $707,026.

lei
Download Presentation

Director’s Report to the National Advisory Council on Drug Abuse

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Director’s Report to the National Advisory Council on Drug Abuse May 17, 2005

  2. Director’s Report to the National Advisory Council on Drug Abuse Budget Update Policy Issues Recent NIDA Activities & Events

  3. Budget Update

  4. 2005Appropriation 2006P.B. 2004Actual $707,026 $693,282 $677,808 $303,104 $313,137 $312,979 $1,010,130 $1,006,419 $990,787 +0.4% +1.2% +3.0% NIDA BUDGET (Thousands) NonAIDS AIDS TOTAL Increase Over Prior Year

  5. Policy Issues

  6. NEW Supplemental Ethics Regulation That Affects ALL NIH Employees Sets out broad prohibitions regarding… Outside activities Holdings Awards Current Status: Pending Response From Employees

  7. Recent NIDA Activities & Events

  8. NIDA PAs and RFAs Just Issued • Collaborative Multisite Research in Addiction (COMRAD) (PA-05-067) • Minority Institutions’ Drug Abuse Research Development Program (MIDARP) (PAR-05-069) • Drug Abuse Dissertation Research: Epidemiology, • Prevention, Treatment, Services and Women and Sex/ • Gender Differences (PAR-05-083) • Inhalant Abuse: Supporting Broad-Based Research Approaches (PA-05-099) • Strategic Program for Innovative Research on Drug • Addiction Pharmacotherapy (SPIRDAP) (RFA-DA-05-009)

  9. PAs and RFAs Recently Issued With Other NIH Components/Agencies 13 New PAs and 4 New RFAs Foci include: Neurobiology Co-morbidity HIV/AIDS Brain Development Research Training Software/Biomedical Computing International Collaboration

  10. NIDA National Institute on Drug Abuse Office of the Director Nora D. Volkow, MD Director Director, AIDS Research HIV/AIDS Research Special Populations Office Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Dr. Jacques Normand Will Provide an Update Office of Extramural Affairs Office of Planning & Resource Management Office of Science Policy & Communications Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD Division of Clinical Neuroscience, Development & Behavioral Treatment Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  11. NIDA National Institute on Drug Abuse Office of the Director Nora D. Volkow, MD Special Population/ Health Disparities Director Director, AIDS Research Special Populations Office Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Dr. Jose Szapocznik Will Report on Minority Health Disparities Workgroup Findings & Recommendations Office of Extramural Affairs Office of Planning & Resource Management Office of Science Policy & Communications Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD Division of Clinical Neuroscience, Development & Behavioral Treatment Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  12. NIDA National Institute on Drug Abuse Office of the Director Nora D. Volkow, MD Director Director, AIDS Research Special Populations Office Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Office of Extramural Affairs Office of Planning & Resource Management Office of Science Policy & Communications Center for the Clinical Trials Network CCTN Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD Division of Clinical Neuroscience, Development & Behavioral Treatment Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  13. The National Drug Abuse Treatment Clinical Trials Network (RFA-DA-05-001) Issued July 7, 2004 Application Receipt Date: October 14, 2004 15 Applications Received -- 4 New Applications Reviewed 13 Scored

  14. CTN Clinical Coordinating Center Contract Awarded to The EMMES Corporation CTN Data and Statistics Center (DSC) Contract Awarded to Duke Clinical Research Institute (DCRI)

  15. Update on New CTN Protocols • Starting Treatment with Agonist Replacement • Therapies (START): compare the effect of • buprenorphine/naloxone and methadone on • liver function 10 sites, January 2006 • Randomized Controlled Trial of Methylphenidate • in Adolescents with ADHD and Substance Use • Disorders 12 sites,Fall 2005 • Methylphenidate in Maintaining Abstinence in • Smokers with ADHD 6 sites, Fall 2005 • Prescription Opioid Addiction Treatment • Study (POATS) ~ 12 sites, Fall 2005

  16. NIDA National Institute on Drug Abuse Office of the Director Nora D. Volkow, MD Director Director, AIDS Research Special Populations Office Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Office of Extramural Affairs Office of Planning & Resource Management Office of Science Policy & Communications Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD Division of Clinical Neuroscience, Development & Behavioral Treatment Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program DPMCDA David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  17. REPORT • from the • Medications Development Program • Work Group • 2005 • National Institute • on Drug Abuse • National Institutes of Health • U.S. Department of Health and Human Services

  18. Committee Members Bankole Johnson, M.D., Ph.D. UT San Antonio Peter Kalivas, Ph.D. Med U South Carolina Herb Kleber, M.D. Columbia University George Koob, Ph.D. Scripps Research Institute Mary Jeanne Kreek, M.D. Rockefeller University Bertha Madras, Ph.D. Harvard Medical School Eric Nestler, M.D., Ph.D. Southwestern University Scott Reines, M.D., Ph.D. Johnson & Johnson Ray White, Ph.D. UC San Francisco NIDA Staff Denise Pintello, Ph.D. M.S.W. Science Writer (Contractor) Jennifer Elcano, M.A.

  19. Summary of Workgroup Recommendations Internal Organization Create a SAB to advise on internal efficiencies & decision making Interactions with other NIDA Divisions Restructure relationships, especially with CCTN and IRP Interactions with Pharmaceutical Companies Establish NIDA as an asset to pharma for abuse liability screening and clinical trials Role of Genetics Develop a human genetic resource via collaborations between MDP and CCTN

  20. Medications Development Scientific Workgroup Members First Meeting: Hyatt Regency Hotel Bethesda, MD March 21-22, 2005 Kenneth Davis, M.D. Lisa H. Gold, Ph.D. Suneel Gupta, Ph.D. Bankole Johnson, M.D., Ph.D. Peter Kalivas, Ph.D. Herb Kleber, M.D. Thomas R. Kosten, M.D. Susan Learned-Coughlin, Pharm.D, Ph.D. Bertha Madras, Ph.D. Eric Nestler, M.D., Ph.D. Charles P. O’Brien, M.D., Ph.D. Kenner Rice, Ph.D.

  21.    Interactions With Other NIDA Components • Starting Treatment with Agonist Replacement • Therapies (START) Study (with CCTN) • Institute-wide Workgroup with Representatives • from CCTN, IRP and all Extramural Divisions

  22. NIDA National Institute on Drug Abuse Office of the Director Nora D. Volkow, MD Director Director, AIDS Research Special Populations Office Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Office of Extramural Affairs Office of Planning & Resource Management Office of Science Policy & Communications Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD Division of Clinical Neuroscience, Development & Behavioral Treatment Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program DBNBR David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  23. NIH Roadmap ACCELERATING MEDICAL DISCOVERY TO IMPROVE HEALTH NIH IC Directors’ Roadmap Retreat April 20, 2005 • Molecular Libraries

  24. NIH Neuroscience Blueprint FY 2005 (Tap = 0.15%) FY 2006 (Tap = 0.30%) Project Team Lead IC GENSAT expansion NINDS Neurobiology of Disease Training Supplements NIMH Neuroscience Inventory NIDA Project Team Lead IC Core Grants NINDS Neuromouse NIMH Training NIDA • Neuroimaging Training • Computational Neuroscience • Neurobiology of Disease

  25. Neuroscience Blueprint ‘06 Training Project Team Laurence Stanford, NIDA, Co-Chair Susan Weiss, NIDA, Co-Chair Beth Babecki, NIDA Robert Baughman, NINDS Allison Chausmer, NIDA Alison Cole, NIGMS Nancy Desmond, NIMH Gayathri J Dowling, NIDA Dennis Glanzman, NIMH Lindsey Grandison, NIAAA Steven Grant, NIDA Kevin Hardwick, NIDCR Deborah Henken, NICHD Chyren Hunter, NEI Henry Khachaturian, NIBIB Teresa Levitin, NIDA Yuan Liu, NINDS Susan Molchan, NIA Andrew Monjan, NIA Juanita Nelson, NIDA Nancy Pearson, NCCAM Nancy Pilotte, NIDA Suman Rao King, NIDA Charles Sharp, NIDA Carol Shreffler, NIEHS David Shurtleff, NIDA Karen Skinner, NIDA Roger Sorensen, NIAAA Daniel Sklare, NIDCD Mark Swieter, NIDA Meredith Temple-O’Connor, NIBIB Susan Volman, NIDA Kenneth Whang, NSF

  26. Training Subgroups • Neuroimaging • Neurobiology of Disease • Computational Neuroscience

  27. Interdisciplinary Predoctoral Trainingin Neuroscience Imaging: Integrating First Principles and Application Purpose: To develop interdisciplinary, predoctoral training programs that integrate imaging technologies, neuroscience applications, and the underlying neurobiological principles with the aim of creating a cadre of scientists who can optimally utilize imaging technologies to address neuroscience questions

  28. Neurobiology of Disease: Training in Translational Research in Neuroscience Purpose: Train MD, PhD and other scientists in the multiple theories, techniques, analytic strategies and objectives of research on the neurobiology of disease

  29. Computational Neuroscience: From Model to Biology and Back Again Purpose: Interdisciplinary training of pre- and postdoctoral fellows competent in the theories, principles and application of the physical, computer, or mathematical sciences to experimental neuroscience

  30. NIDA National Institute on Drug Abuse Office of the Director Nora D. Volkow, MD Director Director, AIDS Research Special Populations Office Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Office of Extramural Affairs Office of Planning & Resource Management Office of Science Policy & Communications Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD Division of Clinical Neuroscience, Development & Behavioral Treatment Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program DCNDBT David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  31. The National Institute on Drug Abuse MRI Study of Normal Brain Development(N=500) Create a database of behavioral and brain MRI development data for 0-18 years Analyze structural-behavioural relationships Develop technique for dissemination of results

  32. Neurobiology of Behavioral Treatment: Recovery of Brain Structure and Function RFA-DA-05-006 22 Applications Received Consequences of Drug Abuse & Alcohol Exposure on Brain & Behavioral Development RFA-DA-05-007 Issued with NIAAA -- 36 Applications Received HIV & Drug Abuse Interventions Among Pregnant Women in Drug Abuse Treatment RFA-DA-05-008 16 Applications Received

  33. NIDA National Institute on Drug Abuse Office of the Director Nora D. Volkow, MD Director Director, AIDS Research Special Populations Office Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Office of Extramural Affairs Office of Planning & Resource Management Office of Science Policy & Communications Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD Division of Clinical Neuroscience, Development & Behavioral Treatment Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program DESPR David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  34. Effectively Breaking the Cycle of Drugs and Crime: Research & Treatment Provide the Answers Sponsored by The Friends of NIDA March 15, 2005

  35. 9 Research Centers 1 Coordinating Center CJ-DATS UpdateCriminal Justice Drug Abuse Treatment Studies • 6 studies in the field focused on: • Reducing HIV risk behavior • Screening for mental illness • Transitioning from prison to community • 2 juvenile justice studies being developed • Community re-entry and HIV risk behaviors • 2 HIV studies being developed: • Men • Women www.cjdats.org

  36. CASA Primary Care Meeting

  37. Screening and Intervention for Youth in Primary Care Settings RFA-DA-04-006 Issued with SAMHSA, HRSA and AHCPR Purpose: Expand the role of primary care in addressing problem drug use—especially marijuana—among youth in the pre-dependency phase of drug abuse. 36 applications 7 awards made in September, 2004: 4 Behavioral Treatment Research 2 Health Services Research 1 Prevention Research

  38. Congressional Hearings Consequences of the Abuse of Anabolic Steroids Testimony before the Committee on Government Reform -- March 17, 2005 Fiscal Year 2006 Budget Request Testimony before the: House Subcommittee on Labor-HHS-Education Approp. -- March 9, 2005 Senate Subcommittee on Labor-HHS-Education Approp. -- April 6, 2005 Methamphetamine Abuse Testimony before the Senate Subcommittee on Labor, HHS, Education, & Related Agencies -- Committee on Appropriations -- April 21, 2005 Substance Abuse and Mental Health Research & Services Testimony before the House Subcommittee on Labor, HHS & Education Committee on Appropriations -- April 27, 2005

  39. NIDA Also Co-sponsored or Had Involvement in… CSAT Annual Grantees Meeting on Adolescent Treatment March 23, 2005 2005 SAMHSA/NIDA Buprenorphine Summit April 11-12, 2005 Impact of Drug Formulation on Abuse Liability, Safety and Regulatory Decisions (CPDD) April 19-20, 2005 Methamphetamine Research Workgroup Meeting March 9-10, 2005 PRIDE 2005 – A Special Research Track from NIDA April 6-9, 2005

  40. 9th Annual PRISM Awards Event Beverly Hills Hotel April 28, 2005 Event will air as a one-hour TV special on FX Network September 4, 2005 at 5:00pm

  41. Cannabis Dependence Treatment: Where We Are, Where We Are Going Issue Workshop Tuesday, May 24, 2005 -- 11:00 am to 12:30 pm Increases in Opioid Analgesic Abuse: Concerns and Strategies Symposium Tuesday, May 24, 2005 -- 2:00 pm to 5:00 pm New Scientific Advances in the Neurobiology of Behavior Symposium Wednesday, May 25, 2005 -- 2:00 pm to 5:00 pm Neurobiology of Compulsive Reward-Seeking Symposium Thursday, May 26, 2005 -- 2:00 pm to 5:00 pm

  42. NIDA-Sponsored Events at CPDD 2005 A record number of posters from CTN research will be presented at this year’s meeting International Forum (June 17th - 19th) Review & Evaluation of NIDA Targets for Potential NIH Roadmap Library Screening Efforts  NIDA Tutorials Translating Basic Research from Neural, Behavioral, & Social Sciences to Prevention Proteomics & Its Application to Drug Abuse Mice Tales: Novel Insights Into Understanding Addiction NIDA Training Mixer NIDA/CPDD Grant-writing Workshop Pharmacogenetics & Drug Abuse Research June 17th June 18th June 20th June 21st June 22nd

  43. Commissioned articles highlighting current progress in the neurobiology of feeding regulation, energy metabolism and obesity Sponsored by the Obesity Research Task Force of the National Institutes of Health • NIDA • NIDDK • NIAAA • NHLBI

More Related